Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722360 | 0.82 | L3MBTL1 (0.44) | SMN1; SMN2EPHX2ALDH1A1MAPT | |
| SCHEMBL824151 | 0.82 | TP53 (0.46) | DPP4DPP8DPP9DPP7HCRTR2 | |
| SCHEMBL25475948 | 0.81 | CA1 (0.38) | CA1CA2MCOLN3ROCK2ROCK1 | |
| SCHEMBL2603251 | 0.80 | EPHX2 (0.46) | MCOLN3EPHX2 | |
| SCHEMBL824146 | 0.80 | EPHX2 (0.39) | MCOLN3ROCK2ROCK1HCRTR2SMN1; SMN2 | |
| SCHEMBL13403906 | 0.80 | HCRTR2 (0.33) | MCOLN3HCRTR2SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL22874873 | 0.77 | ALDH1A1 (0.31) | MCOLN3ROCK2ROCK1HCRTR2ALDH1A1 | |
| SCHEMBL25497902 | 0.77 | EPHX2 (0.34) | MCOLN3EPHX2 | |
| SCHEMBL12125445 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12448240 | 0.77 | CA2 (0.38) | CA1CA2MCOLN3SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3299372-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OFSUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8362037-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | IDO1, IDO2, TDO2 | CA1 2859/4885CA2 2456/4885MCOLN3 2894/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | CA1 2685/4885CA2 2456/4885MCOLN3 4138/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CA1 4407/4885CA2 3426/4885MCOLN3 3034/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CA1 4332/4885CA2 2078/4885MCOLN3 3519/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CA1 4407/4885CA2 3426/4885MCOLN3 3034/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | CA1 4808/4885CA2 4480/4885MCOLN3 4537/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | CA1 4285/4885CA2 1328/4885MCOLN3 1236/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CA1 4407/4885CA2 3426/4885MCOLN3 3034/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CA1 4822/4885CA2 4494/4885MCOLN3 4525/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | CA1 3161/4885CA2 1741/4885MCOLN3 2054/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CA1 4407/4885CA2 3426/4885MCOLN3 3034/4885 |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CA1 4332/4885CA2 2078/4885MCOLN3 3519/4885 |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CA1 4587/4885CA2 3802/4885MCOLN3 2880/4885 |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CA1 4332/4885CA2 2078/4885MCOLN3 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.